Sterling Capital Management LLC Sells 104,041 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Sterling Capital Management LLC lowered its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 91.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 10,053 shares of the medical research company's stock after selling 104,041 shares during the period. Sterling Capital Management LLC's holdings in IQVIA were worth $1,976,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in IQV. Howard Capital Management Inc. grew its position in IQVIA by 4.9% during the fourth quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company's stock worth $225,000 after buying an additional 54 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its holdings in shares of IQVIA by 1.0% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company's stock worth $1,068,000 after purchasing an additional 56 shares in the last quarter. Cypress Wealth Services LLC increased its position in shares of IQVIA by 4.8% in the fourth quarter. Cypress Wealth Services LLC now owns 1,243 shares of the medical research company's stock worth $244,000 after purchasing an additional 57 shares during the period. Harbor Investment Advisory LLC raised its stake in IQVIA by 4.7% in the fourth quarter. Harbor Investment Advisory LLC now owns 1,286 shares of the medical research company's stock valued at $253,000 after purchasing an additional 58 shares in the last quarter. Finally, Magnolia Capital Advisors LLC grew its stake in IQVIA by 2.9% during the fourth quarter. Magnolia Capital Advisors LLC now owns 2,625 shares of the medical research company's stock worth $516,000 after buying an additional 74 shares in the last quarter. 89.62% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have recently commented on IQV. Truist Financial dropped their target price on shares of IQVIA from $263.00 to $216.00 and set a "buy" rating for the company in a research report on Thursday, April 10th. StockNews.com cut IQVIA from a "buy" rating to a "hold" rating in a research note on Wednesday, March 12th. Morgan Stanley boosted their price target on IQVIA from $245.00 to $250.00 and gave the stock an "overweight" rating in a report on Tuesday, February 11th. Citigroup reduced their price objective on IQVIA from $225.00 to $210.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. Finally, Stephens started coverage on IQVIA in a research note on Friday, December 20th. They set an "overweight" rating and a $250.00 target price for the company. Six analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, IQVIA currently has an average rating of "Moderate Buy" and a consensus target price of $241.50.

IQVIA Trading Down 3.2 %

Shares of NYSE IQV traded down $4.78 during midday trading on Friday, reaching $143.66. The stock had a trading volume of 3,302,597 shares, compared to its average volume of 1,403,069. The company's 50 day moving average price is $177.57 and its 200 day moving average price is $197.47. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a twelve month low of $135.97 and a twelve month high of $252.88. The firm has a market cap of $25.33 billion, a price-to-earnings ratio of 19.15, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.